Inhibition of SIRT1 Impairs the Accumulation and Transcriptional Activity of HIF-1α Protein under Hypoxic Conditions by Laemmle, Alexander et al.
Inhibition of SIRT1 Impairs the Accumulation and
Transcriptional Activity of HIF-1a Protein under
Hypoxic Conditions
Alexander Laemmle1, Antje Lechleiter1, Vincent Roh1¤a, Christa Schwarz1, Simone Portmann1,
Cynthia Furer1, Adrian Keogh1, Mario P. Tschan2, Daniel Candinas1, Stephan A. Vorburger1¤b,
Deborah Stroka1*
1Clinic of Visceral Surgery and Medicine, Visceral and Transplantation Surgery, University Hospital Bern and University of Bern, Bern, Switzerland, 2Medical Oncology/
Hematology, Department of Clinical Research, Inselspital, University Hospital Bern and University of Bern, Bern, Switzerland
Abstract
Sirtuins and hypoxia-inducible transcription factors (HIF) have well-established roles in regulating cellular responses to
metabolic and oxidative stress. Recent reports have linked these two protein families by demonstrating that sirtuins can
regulate the activity of HIF-1 and HIF-2. Here we investigated the role of SIRT1, a NAD+-dependent deacetylase, in the
regulation of HIF-1 activity in hypoxic conditions. Our results show that in hepatocellular carcinoma (HCC) cell lines, hypoxia
did not alter SIRT1 mRNA or protein expression, whereas it predictably led to the accumulation of HIF-1a and the up-
regulation of its target genes. In hypoxic models in vitro and in in vivo models of systemic hypoxia and xenograft tumor
growth, knockdown of SIRT1 protein with shRNA or inhibition of its activity with small molecule inhibitors impaired the
accumulation of HIF-1a protein and the transcriptional increase of its target genes. In addition, endogenous SIRT1 and HIF-
1a proteins co-immunoprecipitated and loss of SIRT1 activity led to a hyperacetylation of HIF-1a. Taken together, our data
suggest that HIF-1a and SIRT1 proteins interact in HCC cells and that HIF-1a is a target of SIRT1 deacetylase activity.
Moreover, SIRT1 is necessary for HIF-1a protein accumulation and activation of HIF-1 target genes under hypoxic conditions.
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Introduction
Silent information regulator 2 (Sir2) was initially identified in
Saccharomyces cerevisiae as the first member of the highly conserved
sirtuin family of proteins [1]. The mammalian homolog to Sir2 is
SIRT1 and is the first of seven thus far described sirtuin family
members (SIRT1–SIRT7). Sirtuin proteins are nicotinamide
adenine dinucleotide (NAD+)-dependent deacetylases. Their
dependency on NAD+ suggests that sirtuin activity serves as a
sensor of the cytosolic ratio of NAD+/NADH and thus directly
links sirtuin activity to the metabolic and cellular energy state of a
cell [2,3]. Since the discovery of their enzymatic activity, sirtuins
have been implicated in many important physiological functions
including gene silencing, apoptosis, energy maintenance and
longevity, reviewed in [4].
SIRT proteins have different subcellular localizations and
described functions. For example, SIRT1 and SIRT2 are found
in both the nucleus and cytoplasm. SIRT1 regulate pathways in
metabolism, inflammation and tumorigenesis and SIRT2 func-
tions as a tubulin deacetylase [5]. SIRT3 and SIRT5 are localized
in mitochondria and regulate metabolism and ammonia detoxi-
fication, respectively [6,7]. Recently, it has been suggested that
SIRT5 is also a NAD+-dependent demalonylase and desucciny-
lase [8]. SIRT4 is also located in the mitochondria and inhibits
glutamate dehydrogenase activity [9]. SIRT6 is found in the
nucleus and functions in maintaining genomic stability and glucose
homeostasis [10,11]. SIRT7 interacts with RNA polymerase I
histones to promote Pol I-mediated rRNA transcription in the
nucleolus [12].
SIRT1 is the most studied sirtuin family member, mainly due to
its purported ability to promote longevity in yeast, worms,
drosophila and mammals [13,14,15,16]. However its ability to
increase the life span of lower organisms has recently been called
into question [17]. SIRT1 has also been suggested to have a
critical role in tumorigenesis, however it is controversial whether
SIRT1 is a tumor-suppressor or a tumor-promoter and in fact it is
likely to be tumor-type specific [18]. SIRT1’s deacetylase activity
plays an important function in normal and malignant cellular
processes by targeting histones, which results in a tighter
chromatin structure and transcriptional repression [19]. Impor-
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tantly, SIRT1 also modulates the stability and/or activation
potential of a broad range of transcription factors, such as p53
[20,21], FOXO [22], Ku70 [23], NF-kB [24], E2F1 [25] and
PPARc co-activator 1a (PGC-1a) [26] and as recently described
the hypoxia-inducible transcription factors (HIF), HIF-1 [27] and
HIF-2 [28].
HIF transcription factors are the key mediators of oxygen
homeostasis under hypoxic conditions and they play a vital role in
embryonic development, physiological responses and in disease
pathologies. HIF heterodimers are composed of an oxygen-
sensitive a-subunit and a constitutively expressed b-subunit. HIF-1
and HIF-2 are the best-characterized isoforms and are mainly
regulated by posttranslational modifications of their a-subunit
[29]. Specific prolyl hydroxylases (PHD), which depend on the
substrates oxygen, Fe (II) and 2-oxoglutarate, target the a-subunit
under normoxic conditions [30]. Hydroxylation of two proline
residues (HIF-1a: P402 and P564 and HIF-2a: P405 and P531)
within the oxygen-dependent degradation domain serve as a
recognition site for the von Hippel-Lindau tumor suppressor
(pVHL), a ubiquitin E3 ligase, which leads to the proteosomal
degradation of the a-subunit [31,32,33]. In the absence of oxygen,
PHDs are inactive and thereby HIFa proteins are stabilized.
Accumulated HIFa protein translocates to the nucleus, forms a
dimer with HIFb and along with co-activators such as p300-CBP
binds to hypoxia responsive elements (HRE) of target genes. HIF-1
and HIF-2 share the same consensus sequence G/ACGTG in
their target genes [34] and have several common gene targets such
as erythropoietin (EPO), vascular endothelial growth factor
(VEGF) and glucose transporter 1 (GLUT-1) [35]. However, they
also have unique transcriptional targets, HIF-1 is responsible for
the regulation of many genes encoding enzymes involved in the
glycolytic pathway, as well as the pro-apoptotic gene BCL2
adenovirus E1B-interacting protein 1 (BNIP3) and carbonic
anhydrase 9 (CA9) [36,37].
Recent reports have linked HIF and sirtuin families together by
demonstrating that SIRT1, SIRT3 and SIRT6 can regulate the
activity of HIF proteins [27,28,38,39]. With regards to the
interaction between SIRT1 and HIF proteins, Lim et al.
demonstrated that SIRT1 binds to and deacetylates HIF-1a at
lysine 674. This interaction blocks p300 recruitment to the
promoter of HIF-1 target genes and thereby represses HIF-1
transcriptional activity [27]. Conflictingly, Dioum et al. have
reported that SIRT1 does not target HIF-1a, rather it deacetylates
HIF-2a, and their interaction promotes HIF-2 transcriptional
activity [28]. In addition, because SIRT1 is a redox sensor and
dependent on the metabolic status of the cell, its regulation by
hypoxia has been a point of interest. In one report, SIRT1 is down
regulated in hypoxic conditions due to decreased NAD+ levels
[27], while in another report it is up regulated in a HIF-dependent
manner [40]. From the current literature, one can conclude that
the interaction between SIRT1 and HIF-1 and the resulting
outcome of their interactions is still unclear.
Previously generated data from our lab were also in conflict with
the above-mentioned studies. Therefore, here, we report our
findings on the involvement of SIRT1 and HIF-1 in hypoxic
conditions. First we looked at the influence of hypoxia on SIRT1
expression. We consistently observed that SIRT1 protein or
mRNA was not modified in three different HCC cell lines cultured
under hypoxic conditions. Abundant SIRT1 and HIF-1a protein
are simultaneously expressed in hypoxic cells. From this
observation and considering the reported negative association
between SIRT1 and HIF-1 [21], we questioned whether inhibiting
SIRT1 activity would thereby augment HIF-1 function under
hypoxic conditions. Our data demonstrates that inhibition of
SIRT1 activity reduces the hypoxia-induced transcriptional
activity of HIF-1 gene targets and the accumulation of HIF-1a
protein itself. We show that this regulation is relevant in vivo by
demonstrating that SIRT1 inhibition leads to a decreased HIF-
mediated response to systemic hypoxia. In addition, SIRT1
inhibition resulted in growth inhibition in a mouse xenograft
tumor model of HCC. And finally we demonstrate that
endogenous SIRT1 and HIF-1a co-immunoprecipitate and HIF-
1 is a target of SIRT1 deacetylase activity. Taken together these
data suggest that SIRT1 targets HIF-1a protein and that this
interaction is required for HIF-1a activity in hypoxic conditions.
Results
SIRT1 and HIF-1a are simultaneously expressed in
hypoxic cells
HIF-1 is tightly regulated by oxygen availability and functions
predominantly in hypoxic conditions. In order to demonstrate that
SIRT1 is necessary for the accumulation of HIF-1a protein, we
first verified that SIRT1 and HIF-1a proteins are co-expressed in
hypoxic conditions. SIRT1 protein was strongly expressed in
Hep3B, HepG2 and Huh7 HCC cells lines in normal culture
conditions as well as in cells incubated at 1% O2 (Figure 1A). As
predicted, HIF-1a protein was not detected in cells cultured at
21%O2 and was stabilized in cells incubated at 1%O2 (Figure 1A).
Stabilization of HIF-1a protein led to the transcriptional increase
of HIF-1 target genes BNIP3, CA9 as well as EPO, a target gene
shared with HIF-2 (Figure 1B). To further verify that SIRT1
protein is not altered by hypoxia, HCC cells were exposed to 1%
O2 for up to 48 hours. There was no change in SIRT1 protein or
mRNA in cells exposed for 12, 24 or 48 hours to 1% O2
(Figure 1C & D). In addition, there was no significant change in
SIRT1 mRNA in Hep3B cells exposed to more severe hypoxia of
0.1% O2 for 24 hours (Figure 1E). These data show that both
SIRT1 and HIF-1a are present in cells under hypoxic conditions
and HIF-1 is transcriptionally active. Moreover, unlike HIF-1a,
SIRT1 expression is not tightly regulated by hypoxia in HCC cells.
Inhibition of SIRT1 decreases HIF transcriptional activity
and suppresses HIF-1a protein accumulation
As demonstrated above, we observed a simultaneous expression
of both SIRT1 and HIF-1a protein under hypoxic conditions. A
recent report by Lim et al. has suggested that SIRT1 negatively
regulates HIF-1 activity by suppressing the transcriptional
regulation of its target genes [27]. Following the model proposed
by their data, inhibition of SIRT1 should provoke an exaggerated
HIF-mediated response. Therefore, we tested the effect of
inhibiting SIRT1 on HIF-1 activity using sirtinol, a cell permeable
specific inhibitor of SIRT deacetylase activity [41]. The IC50 value
of sirtinol is 70 mM for SIRT1 activity; hence concentrations of 25,
50 and 100 mM were used in this study. First, we confirmed the
functionality of sirtinol on SIRT1 deacetylase activity in HepG2
cells. HepG2 cells have abundant SIRT1 protein, as well as an
intact p53 response to DNA damage. The acetylation of lysine 382
of p53 is modulated by SIRT1 [21]. We demonstrated that sirtinol
had no detectable effect on the lysine 382 acetylation in the
absence of DNA damage, whereas, sirtinol produced a time-
dependent increase of acetylated p53 in cells treated with the DNA
damaging agent, doxorubicin (Figure S1). These data confirm that
sirtinol is an efficient inhibitor of SIRT1 activity in vitro. We next
investigated the effect of inhibiting SIRT1 activity on HIF-
mediated transcriptional activation. Cells were transfected with a
HRE reporter construct that contains multiple HRE sites and is
specifically induced by HIF proteins and thus represents a direct
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measurement of HIF activation [42]. Twenty-four hours after
transfection, cells were treated with increasing doses of sirtinol and
incubated 24 hours at 1% O2. Hypoxia increased reporter activity
38-fold and there was no significant change in cells treated with
DMSO at a concentration equal to the amount needed to treat
cells with 100 mM sirtinol. There was a dose-dependent decrease
of HIF-1 transcriptional activity in cells treated with sirtinol. A
significant reduction of reporter activity was observed with 50 mM
Figure 1. SIRT1 and HIF-1a are simultaneously expressed in hypoxic cells. A. Hep3B, HepG2 and Huh-7 cells were exposed to (N) normoxia
(21% O2) or (H) hypoxia (1% O2) for 8 hours. SIRT1 and HIF-1a proteins were detected by Western blot. An antibody against Sp1 was used as a control
for equal loading. A representative blot of 3 independently performed experiments is shown. B. Total RNA was isolated from Hep3B cells exposed to
1% O2 for 16 hours. RT-qPCR was performed and relative fold increase of target gene mRNA was calculated by comparing DCt values of cells cultured
at 21% O2 to DCt values of cells exposed to 1% O2. Relative mRNA was increased 10.765-fold for BNIP3, 21.864-fold for CA9 and 101617-fold.
Columns, mean values from 3 independent experiments. Bars,6SD. C. Hep3B and HepG2 cells were exposed to (N) normoxia (21% O2) or (H) hypoxia
(1% O2) for 12, 24 and 48 hours. SIRT1 and a-tubulin proteins were detected in total cell lysates by Western blot. A representative blot of 6
independently performed experiments is shown. D. Total RNA was isolated from Hep3B cells exposed to 1% O2 for 12, 24 and 48 hours and DCt
values of SIRT1 mRNA was compared to cells cultured at 21% O2 by RT-qPCR. Columns, mean values from 6 independent experiments. Bars, 6SD. E.
Total RNA was isolated from Hep3B cells exposed to 1% O2 and 0.1% O2 for 24 hours and DCt values of SIRT1 mRNA was compared to cells cultured
at 21% O2 by RT-qPCR. Columns, mean values from 6 independent experiments. Bars, 6SD. 1%O2.
doi:10.1371/journal.pone.0033433.g001
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and 100 mM sirtinol (Figure 2A). We next verified that inhibition
of SIRT1 activity alters the transcriptional activity of HIF-1 target
genes. Pretreatment with 100 mM sirtinol significantly reduced the
hypoxic induction of specific HIF-1 targets BNIP3 and CA9
mRNA as well as EPO mRNA (Figure 2B). Although, sirtinol
specifically inhibits SIRT1, it also affects other members of the
sirtuin family such as SIRT2 with an IC50 value of 40 mM [41].
Therefore to verify that the effect of sirtinol on repressing HIF-
mediated transcriptional activity is at least in part due to the
inhibition of SIRT1, cells were infected with lentiviruses carrying
shRNA sequences targeting SIRT1. Targeted disruption of SIRT1
with clone shSIRT1_1958 led to a nearly complete knockdown
whereas, shSIRT1_3206 resulted in a partial knockdown of
SIRT1 protein compared to parental and SHC002 controls
(Figure 2E). Cells infected with lentiviruses expressing clone
shSIRT1_1958 significantly reduced the hypoxic induction of
CA9 and EPO mRNA (Figure 2C). These data demonstrate that
inhibition of SIRT1 activity with a small molecule inhibitor and a
genetic knockdown leads to a strong decrease of HIF-1-mediated
transcriptional activity.
We next questioned, whether loss of HIF transcriptional activity
by inhibiting SIRT1 was due to an effect on HIF-1a protein itself.
Hep3B cells were incubated with sirtinol for 16 hours and then
exposed to 1% O2 for 4 hours. HIF is mainly regulated by
hydroxylation of its a-subunit, so as expected, in normoxic Hep3B
cells HIF-1a protein was degraded and nearly undetectable,
whereas it was efficiently stabilized under hypoxia. Interestingly,
inhibition of SIRT1 activity with sirtinol led to a dose-dependent
repression of HIF-1a protein accumulation (Figure 1D). Impor-
tantly, HIF-1a was detected by using an antibody that is specific
for HIF-1a and does not cross react with HIF-2a [43]. To verify
that the repressive effect on HIF-1a expression was due to SIRT1
inhibition, the experiment was repeated in Hep3B with a
knockdown of SIRT1 expression. SIRT1 knockdown cells had
an impaired ability to accumulate HIF-1a protein; the efficiency of
SIRT1 knockdown correlated with the suppression of HIF-1a
protein, with a stronger effect achieved in cells infected with
lentivirus shSIRT1_1958 (Figure 2E).
To determine the kinetics of sirtinol-mediated HIF-1a protein
repression, Hep3B cells were either incubated with sirtinol for 16,
2 and 0 hours before exposing them to hypoxia for 4 hours or
sirtinol was added to the cells 2 hours after exposure to hypoxia.
Sirtinol added at the onset of hypoxia inhibited the accumulation
of HIF-1a protein. An even stronger repressive effect was observed
when cells were pre-exposed to sirtinol for 2 or 16 hours. Addition
of sirtinol to cells after two hours under hypoxia, resulted in no
reduction of HIF-1a protein (Figure 2F). Using the same
experimental setting, we checked whether SIRT1 inhibition
impairs the transcription of HIF-1a. HIF-1a mRNA levels were
not modified by sirtinol (Figure 2G). RT-qPCR showed similar
results as equivalent DCt values were calculated for each time
point and condition tested (data not shown). This analysis of HIF-
1a mRNA, suggests that impairment of HIF-1a protein accumu-
lation is not a result of an inhibition of its transcription.
The degradation of HIFa proteins is mediated by VHL. To
determine whether the sirtinol-induced repression of HIF-1a
protein is dependent on VHL, we used a VHL-deficient renal cell
carcinoma, RCC4 VHL2/2 and a VHL reconstituted, RCC4
VHL+/+ cell lines. RCC4 VHL2/2 cells express HIF-1a protein
constitutively, even under normoxic conditions [44,45]. Exposure
of RCC4 VHL+/+ cells to hypoxia for 4 hours, led to the
induction of HIF-1a protein. Two hours of sirtinol pretreatment
strongly inhibited hypoxia-induced HIF-1a accumulation in
RCC4 VHL+/+ cells (Figure 2H). In RCC4 VHL2/2 cells,
sirtinol repressed HIF-1a protein under both normoxic and
hypoxic conditions, thus demonstrating that sirtinol-mediated
HIF-1a repression is independent of VHL (Figure 2H). Interest-
ingly, RCC4 VHL2/2 cells required a longer treatment time
with sirtinol (16 hours) in order to decrease HIF-1a protein levels.
The shorter incubation time (2 hours) with sirtinol was insufficient
to observe an effect on HIF-1a protein (Figure 2H). This
observation is consistent with our findings in Hep3B cells
(Figure 2F), indicating that sirtinol-mediated repression of HIF-
1a is due to a decrease of newly stabilized HIF-1a protein, rather
than enhanced degradation of preformed (mature) HIF-1a.
To verify that the inhibition of SIRT1 represses HIF-1a in a cell
independent manner, two additional cell lines were tested. Similar
to the results obtained in Hep3B cells, sirtinol pretreatment
decreased hypoxia-induced HIF-1a protein stabilization in
HepG2 and Huh7 cells (Figure S2). Taken together, these results
show that reducing SIRT1 protein expression or deacetylase
activity impairs the ability of HIF-1a protein to accumulate under
hypoxic conditions and to transcriptionally activate its target
genes. Moreover, SIRT1 is not regulating HIF-1a at the
transcriptional level but it is required for the post-translational
stabilization and accumulation of HIF-1a protein.
SIRT1 overexpression enhances hypoxic stabilization of
HIF-1a protein
The data presented above suggest that the inhibition of SIRT1
impairs the accumulation of HIF-1a protein under hypoxic
conditions. We next tested if enhanced SIRT1 expression has a
stabilizing effect on HIF-1a protein. Hep3B cells were infected
with lentiviruses expressing SIRT1 wild type protein or SIRT1
H363Y protein, which is point-mutated in the catalytic domain of
SIRT1 and therefore enzymatically inactive [46]. Clones of
Hep3B cells overexpressing wild type or mutated SIRT1 were
incubated with increasing concentrations of dimethyloxallyl
glycine (DMOG) a competitive inhibitor of HIF PHDs used to
stabilize HIF-1a under normoxic conditions. Cells overexpressing
wild type SIRT1 showed a greater sensitivity to DMOG, as lower
concentrations of DMOG were able to stabilize HIF-1a in SIRT1
wild type cells compared to SIRT1 mutated and control cells
(Figure 3). Overexpression of SIRT1 showed a stronger effect on
the accumulation of HIF-1a than SIRT1 H363Y, thus suggesting
that SIRT1 deacetylase activity plays a role in the stabilization of
HIF-1a.
HIF-1a interacts with SIRT1 protein and is a target of its
deacetylase activity
We next questioned whether HIF-1a is a target of SIRT1
deacetylase activity. There is contradictory literature on whether
there is a direct interaction between HIF-1a and SIRT1 [27,28].
Therefore, we tested if endogenous proteins co-immunoprecipitate
in the cells used in this study. Hep3B cells were treated with
DMOG for 5 hours to stabilize HIF-1a under normoxic
conditions. SIRT1 protein was detected in the cytoplasmic and
nuclear fraction. A strong HIF-1a signal was found in the nuclear
fraction, and a lower signal was detected in the cytoplasmic
fraction (Figure 4A). Using endogenously expressed cytoplasmic
proteins, we observed that HIF-1a immunoprecipitated with
extracts for SIRT1, and likewise, SIRT1 is detected in extracts
immunoprecipitated for HIF-1a (Figure 4B). In summary, our
data are in agreement with others, and suggest that SIRT1 and
HIF-1a proteins physically interact [27,39]. From this data we
hypothesize that SIRT1 may exert its effects on HIF-1a protein
stability through a physical interaction.
Inhibition of SIRT1 Impairs HIF-1 Activity
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Having demonstrated that SIRT1 and HIF-1a physically
interact in Hep3B cells, we investigated whether HIF-1a is a
target of SIRT1 deacetylase activity. Hep3B cells were infected
with lentiviruses containing shRNA against SIRT1 or SHC002 as
negative control. As shown in Figure 2E, SIRT1 knockdown leads
to a loss of HIF-1a protein. Therefore, to investigate changes in
the acetylation level of HIF-1a protein in the SIRT1 knockdown
cells, MG132 was added to avoid HIF-1a proteosomal degrada-
tion. HIF-1a proteins were immunoprecipitated then analyzed by
Western blot using a polyclonal anti-acetyl-lysine antibody. There
was a clear increase of acetylated HIF-1a protein in the SIRT1
knockdown cells compared to the SHC002-infected control
(Figure 4C). From this experiment we can conclude that SIRT1
deacetylates HIF-1a protein, as knocking down of SIRT1 led to an
increase of HIF-1a acetylation. We however cannot conclude that
altering the acetylation state of HIF-1a affects its stabilization
under hypoxic conditions.
Cambinol blocks HIF-dependent gene regulation in vivo
We next tested if pharmacologically targeting SIRT1 can also
influence HIF activity in vivo. Cambinol, a cell permeable b-
naphthol compound inhibits the NAD+-dependent deacetylase
activity of SIRT1 and SIRT2 (IC50= 56 mM and 59 mM,
respectively) and exhibits no inhibition against class I or II histone
deacetylase activity [47]. Unlike sirtinol, cambinol can be used in
vivo and was shown to effectively inhibit xenograft BCL6-
expressing Burkitt lymphoma growth in mice [47]. In a first step,
the suppressive effect of cambinol was tested and compared to
sirtinol in HepG2 cells in vitro (Figure 5A). HepG2 cells are
tumorigenic in immune deficient mice, therefore provide the
opportunity to test the effect of SIRT1 inhibition in an HCC
xenograft model. Inhibition of SIRT activity with cambinol led to
a dose-dependent repression of HIF-1a protein accumulation in
HepG2 cells in vitro. Cells treated with sirtinol were used for
comparison (Figure 5A). We previously reported that in mice
exposed to 6% oxygen HIF-1a protein accumulates in various
tissues and activates HIF target genes [48]. Therefore, we tested if
inhibition of SIRT1 represses a HIF-driven response in vivo. Mice
were pre-treated with cambinol for 2 hours and then exposed to
6% oxygen for 6 hours. Analysis of mouse tissues showed that
there was a significant decrease of EPO mRNA in the kidney and
the liver in mice pre-treated with cambinol, whereas, pre-
treatment with cambinol did not reduce EPO mRNA in the
brain (Figure 5B). In HCC, HIF proteins play an important role in
tumor progression and their expression is a poor prognostic
indicator [49,50]. Therefore to examine the effect of inhibiting
SIRT1 on HIF expression and function in HCC, 0.56106
luciferase-labeled HepG2 cells were injected into the subcapsular
space of the left liver lobe in immune deficient Rag2/common
gamma-null mice. On day 8 after injection, intrahepatic tumors
were visible by bioluminescent imaging. Starting on day 9, an i.p.
injection of cambinol (100 mg/kg) or vehicle was administered
daily, 5 times per week. A preliminary study verified the
concentration of cambinol used had no toxic effect to the animals;
they displayed no weight loss or increased levels of serum
transaminases (ALT & AST) (data not shown). Animals were
euthanized on day 30 due to sizeable tumor growth in the vehicle-
treated group. Animals treated with cambinol had overall smaller
tumors than vehicle treated controls (Figure 5C). Analysis of tumor
tissue at time of excision revealed lower mRNA levels of the HIF
target gene and pro-angiogenesis factor, VEGF in cambinol
treated mice (Figure 5D). Histological examination of the tumors
of cambinol treated animals showed less vascular density and
intratumoral hemorrhage (Figure 5E). Taken together, these in vivo
observations support our in vitro data and further demonstrate that
loss of SIRT1 activity impairs HIF-mediated responses to hypoxia.
Discussion
SIRT1 and HIF independently regulate key metabolic pathways
important in biological processes, such as tumorigenesis and aging,
therefore, a clear understanding of the interaction between these
two protein families is of high scientific and clinical interest. There
are discrepancies present in the current literature regarding the
interaction and consequence of SIRT1 on HIF-1 activity. Here we
present our findings that suggest SIRT1 is necessary for the
accumulation of HIF-1a protein and therefore is a positive
regulator of HIF-1 transcriptional activity.
We showed that HCC cells have high SIRT1 protein expression
and that there is a simultaneous expression of both HIF-1a and
SIRT1 proteins under hypoxic conditions. SIRT1 protein or
mRNA levels were not altered in cells under hypoxic conditions for
up to 48 hours. Our findings in human HCC cells are similar to
those reported in adult rat cardiac myocytes in which SIRT1
protein levels were not increased by hypoxia alone. However in
cardiac myocytes, SIRT1 was strongly increased in cells exposed to
repetitive cycles of hypoxia/re-oxygenation [51]. Nevertheless,
these data are not in agreement with studies that report hypoxia up-
regulates SIRT1 in a HIF-dependent manner [40] or that hypoxia
down-regulates SIRT1 due to decreased NAD+ levels [27].
Figure 2. SIRT1 inhibition represses HIF-1 transcriptional activity and HIF-1a protein. A. Hep3B cells were co-transfected with luciferase
reporter carrying multiple HREs and a renilla luciferase control plasmid. Twenty-four hours after the transfection, cells were treated with 25, 50 and
100 mM sirtinol and exposed to hypoxia for 24 hours. Dual luciferase activities were measured and firefly values were normalized by renilla values.
Luciferase activity was reduced from 35-fold of DMSO-treated controls to 32-fold with 25 mM sirtinol, p = 0.2611; to 23-fold with 50 mM, *p= 0.0225
and to 10.5-fold with 100 mM ***p= 0.0009. Columns, mean of triplicates from one representative experiment (n = 3, independent experiments) Bars,
6SD. B. Hep3B cells were either treated with 100 mM sirtinol or an equivalent concentration of DMSO for 4 hours and then exposed to 1% O2 for
16 hours. Fold increase was calculated from DCt values of hypoxic cells to average DCt values of cells cultured at 21% O2 in DMSO. BNIP3 mRNA was
reduced from 1461.5 to 3.461-fold (***p = 0.0005), CA9 mRNA from 2163.5 to 3.860.8-fold (**p = 0.0011) and EPO from 100611.5 to 6.161.6-fold
(**p = 0.0012) Columns, mean of 3 independent experiments; bars, 6SD. C. Hep3B cells were infected with lentiviral vectors containing shRNA
sequences that target SIRT1 (shSIRT1_1958) or with a scrambled control (SHC002). Five days after transduction cells were exposed to hypoxia for
12 hours. The relative fold increase of mRNA in hypoxic cells was calculated compared to normoxic controls. CA9 mRNA reduced from 27- to 5.5-fold
(**p = 0.008) and EPO from 120- to 18-fold (**p = 0.004). Columns, mean of 3 independent experiments; bars,6SD. D. Hep3B cells were treated with 0,
25, 50 and 100 mM sirtinol or an equivalent concentration of DMSO (D) for 16 hours and then exposed to 21% O2 (N) or 1% O2 (H) for 4 hours. Whole
cell lysates were analyzed by Western blot using antibodies against HIF-1a. a-tubulin was used as a loading control. A representative blot of 6
independently performed experiments is shown. E. Hep3B cells were infected with lentiviral vectors containing shRNAs targeting SIRT1
(shSIRT1_1958 and shSIRT1_3206) or with a scrambled negative control (SHC002). Five days after transduction, cells were exposed to hypoxia for
4 hours and SIRT1 and HIF-1a were analyzed by Western blot. Representative blot of 3 independently performed experiments. F–G. Hep3B cells were
treated with 100 mM sirtinol for 16, 2 and 0 hours before and 2 hours after the exposure to hypoxia for a total of 4 hours. HIF-1a expression was
analyzed by Western blot and by RT-qPCR. H. RCC4 VHL+/+ and RCC4 VHL2/2 cells were pretreated with 100 mM sirtinol or DMSO for 2 or 16 hours,
followed by 4 hours exposure to 21% O2 (N) or 1% O2 (H). Whole cell lysates were analyzed for HIF-1a by Western blot.
doi:10.1371/journal.pone.0033433.g002
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Our observation that abundant SIRT1 and HIF-1a proteins are
expressed simultaneously in hypoxic HCC cells is important as it
does not correspond with the proposed model of Lim et al., in
which they suggest that SIRT1 deacetylates HIF-1 and impairs
HIF-1 transcriptional activity [27]. We observe a robust
transcriptional increase of HIF-1 target genes in hypoxic cells
that possess high endogenous levels of SIRT1 protein. Moreover,
if SIRT1 were a negative regulator of HIF-1a, we would expect an
enhanced transcriptional response of HIF-1 target genes by
inhibition of SIRT1 protein. Here we report the opposite effect;
the transcriptional activity of HIF target genes was consistently
impaired with the inhibition of SIRT1. Inhibition of SIRT1
activity with genetic knockdown or small molecule inhibitors
repressed the up-regulation of HIF-1 target genes in vitro. These
results were substantiated in vivo with mouse models of systemic
hypoxia and HCC tumor xenografts. Dioum et al. also proposed
that SIRT1 positively regulates cellular responses to hypoxia,
albeit in a manner dependent on HIF-2 [16]. Lim et al. overcame
the discrepancies in their data by demonstrating that SIRT1
facilitated the transcriptional activity of HIF-2a, whereas it
repressed HIF-1a activity [17]. Our data show that SIRT1 is
necessary for the hypoxic up-regulation of specific HIF-1 target
genes, CA9 and BNIP3; a HIF-1-mediated increase of their
mRNA was impaired with SIRT1 inhibition. Moreover, we
demonstrate that SIRT1 is necessary for the accumulation of HIF-
1a protein itself, using an antibody that is specific for HIF-1a and
does not cross-react with HIF-2a [32]. HIF-1a did not accumulate
in cells treated for at least 2 hours with sirtinol or cambinol before
exposure to hypoxia or in cells with knocked down SIRT1 protein
expression. Rane et al. also reported that knockdown of SIRT1
results in a loss of HIF-1a protein expression in cardiac myocytes,
although the effect was more pronounced in cells exposed to
hypoxia/re-oxygenation than hypoxia alone [51]. Taken together,
our data clearly suggests that SIRT1 positively regulates the
transcriptional activity of HIF-1. To address the conflicting reports
on the regulation of HIF-1a by SIRT1, experimental conditions
and cell or tissue type specificities may need to be taken in
consideration.
The mechanism of how SIRT1 inhibition impairs the
accumulation of HIF-1a protein is still unclear. Our data, in
agreement with others, show an endogenous interaction between
SIRT1 and HIF-1a [27,39]. Lim et al. identified lysine 674 in
HIF-1a as a target of SIRT1 deacetylase activity [27]. In
agreement with their data, we showed that inhibiting SIRT1 led
to an increased acetylation of HIF-1a protein. However, we
cannot conclude that altering the acetylation state of HIF-1a
directly influences its stability. Conflicting data regarding the
acetylation of HIF-1a have been reported [52]. In a yeast two-
hybrid assay, interaction of HIF-1a with an acetyltransferase
termed mouse ARD1 (mARD1), was shown to enhance
acetylation of a specific lysine residue (K532) within the ODD of
HIF-1a. The same group described enhanced binding of VHL to
acetylated HIF-1a, thus leading to an increase in its proteosomal
degradation [53]. However, it was shown in several other studies,
that the human variant of ARD1, hARD1 does not acetylate HIF-
1a [54,55]. In addition, several reports present different
mechanisms in which class I and class II histone deacetylase
enzymes regulate the stabilization and transcriptional activation of
HIF-1a [52,56].
The complexity of the regulation of HIF activity is becoming
more apparent. SIRT1 could be in part functioning by targeting
enzymes regulating HIF activity. PHD2 is the main PHD
responsible for the hydroxylation of HIF-1a under normoxic
conditions [57]. SIRT1 was shown to down-regulate PHD2
through its deacetylase function [51]. Inhibition of SIRT1
deacetylase activity could result in higher PHD2 activity leading
to the loss of accumulation of HIF-1a. In addition, new proteins
such as pyruvate kinase M2 (PKM2) were described as being
required for HIF-1 transactivation activity [58]. PKM2 interacts
directly with HIF-1a and promotes transactivation of HIF-1 target
genes by enhancing HIF-1 binding and p300 recruitment to
hypoxia response elements. PKM2 activity is regulated by post-
translational modifications such as hydroxylation [58], tyrosine
phosphorylation [59], sumoylation [60] and lysine acetylation
[61]. On could hypothesize that sirtuins could exert an additional
level of control over HIF proteins by the post-translational
modification of PKM2.
SIRT1 and HIF-1 are both highly conserved and constitutively
expressed proteins that are positive factors needed to resolve
metabolic and oxidative stress. In addition, both are required for
normal tissue development [62] and are both targets for post-
transcriptional regulation by the microRNA, miR-119a-5p [51].
Therefore, as suggested by our findings, it seems plausible that
their interaction should facilitate, not hinder each other’s function
for normal tissue homeostasis. Although SIRT1 and HIF-1 are
vital for the maintenance of healthy tissue, their expression may
also have undesirable consequences in a malignant environment.
Our observation that SIRT1 is highly expressed in HCC cell lines
is consistent with that of others who reported that SIRT1 is
overexpressed in liver, colon, breast, and prostate cancers and
squamous cell carcinomas [63,64]. Cancer cells have the ability to
hijack cellular processes that can promote their survival under
harsh conditions that exist in a tumor microenvironment. SIRT1
overexpression could provide tumor cells a survival advantage.
Transient overexpression of SIRT1 was shown to be sufficient to
stimulate basal rates of autophagy, which is used by cancer cells to
Figure 3. SIRT1 overexpression stabilizes HIF-1a protein. Hep3B cells were infected with lentiviruses expressing either SIRT1wt or mutated
SIRT1 H363Y. Three days after transduction clones were selected and expanded. Hep3B cells with SIRT1wt clone 5 and clone 13 or SIRT1 H363Y lines
were incubated with 0, 20 and 50 mM DMOG for 2 hours. Whole cell lysates were analyzed for SIRT1 and HIF-1a by Western blot. A representative blot
of 3 independently performed experiments is shown.
doi:10.1371/journal.pone.0033433.g003
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help them survive under stressful tumor microenvironment
conditions [65]. In this context, the inhibition of SIRT1 is
becoming a novel approach for the development of new treatment
strategies for some cancers. However, many of the available sirtuin
inhibitors have limited potency and isoform specificity. This has
prompted the development of novel inhibitors that can distinguish
between sirtuin family members to better target the desired
effector function [66]. Studies reporting that sirtuins can influence
the activity and function of HIF transcription factors are of high
interest, since HIF proteins are also frequently overexpressed in
cancers, are driving force in many steps of cancer progression and
are a negative predictors for patient outcome (reviewed in [67]). As
suggested by our data, an additional benefit of targeting SIRT1
would be the inhibition of HIF-1 activity. However, as introduced
earlier, SIRT1 targets the activity of many other transcription
factors and co-activators. An undesirable effect of inhibiting
SIRT1 activity could be obtained if, for example, NF-kB is
constitutively activated in the targeted cancer cells. SIRT1
suppresses NF-kB signaling [24,68] and release of this suppression
could stimulate cancer cell proliferation, inhibit apoptosis and
increase angiogenesis and metastasis [69].
Interestingly, SIRT1 is not the only sirtuin family member
shown to regulate HIF-1 function. SIRT6 expression interferes
with HIF-1-mediated transcriptional activity by interfering at the
promoter of target genes [38]. SIRT3, a mitochondrial deacetylase
functions as a tumor suppressor protein by its ability to inhibit the
generation of reactive oxygen species (ROS) [70]. SIRT3 regulates
HIF-1 by maintaining low levels of ROS allowing PHD to be
active, which results in the degradation of the a-subunit. With loss
of SIRT3 expression cellular ROS levels increase, reducing PHD
activity, thus leading to an increase of HIF-1a expression [39]. In
agreement with the findings described above, we observe lower
SIRT3 and SIRT6 mRNA expression in 5 out of 7 liver cancer
cells lines tested and compared to normal human hepatocytes
(unpublished observation). These observations provide additional
arguments for the necessity of potent sirtuin activators and
inhibitors that can distinguish between the different family
members.
Understanding the connection between sirtuin and HIF
proteins is complex and the current literature is in part,
contradictory. Our data add information to help understand the
interaction between SIRT1 and HIF-1 in order to gain more
Figure 4. SIRT1 and HIF-1a co-immunoprecipitate. A. Hep3B cells
were treated with 125 mM DMOG for 5 hours. Cytoplasmic and nuclear
protein fractions were prepared. Twenty-five mg nuclear proteins and
50 mg cytoplasmic proteins were analyzed for SIRT1 and HIF-1a by
Western blot. Sp1 was used as a nuclear fraction marker and a-tubulin
for the cytoplasmic fraction. A representative blot of 3 independently
performed experiments is shown. B. Cytoplasmic proteins (1250 mg)
prepared in (A) were immunoprecipitated with a rabbit polyclonal SIRT1
antibody, chicken polyclonal HIF-1a antibody or a rabbit IgG1 control
antibody. Immunoprecipitated proteins were subjected to Western blot
analysis. A representative blot of 3 independently performed exper-
iments is shown. C. SIRT1 inhibition leads to increased acetylation of
HIF-1a. Hep3B cells were infected with lentiviral vectors containing
shRNA against SIRT1 (shSIRT1_1958 or shSIRT1_3206) or scrambled
shRNA (SHC002) as a negative control. Seven days post-infection, cells
were incubated under hypoxia for 5 hours in the presence of 10 mM
MG132. Whole cell lysates (2 mg) were immunoprecipitated with a
mouse monoclonal HIF-1a antibody (2 mg) and precipitates were
analyzed by Western blotting with a rabbit polyclonal anti-acetyl-lysine
and a polyclonal chicken anti-HIF-1a antibody. Whole cell lysates (WCL:
100 mg) were used as input controls and were analyzed for SIRT1 and a-
tubulin. A representative blot of 2 independently performed experi-
ments is shown.
doi:10.1371/journal.pone.0033433.g004
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Figure 5. Inhibition of SIRT1 with cambinol impairs hypoxic response in vivo. A. HepG2 cells were treated with 50 and 100 mM sirtinol or
cambinol or an equivalent concentration of DMSO (0) for 16 hours and then exposed to 21% O2 (N) or 1% O2 (H) for 4 hours. A representative blot of
2 independently performed experiments is shown. B. Wild type C57BL/6 mice were administered 100 mg/kg cambinol 2 hours prior to exposure to
6% O2 for 6 hours. Total RNA was isolated from liver, kidney and brain tissues. RT-qPCR was performed and DCt values of EPO mRNA of hypoxic mice
treated with vehicle or cambinol were compared the average delta Ct values of vehicle-treated normoxic mice. The fold change of EPO mRNA was
from 221665 (control) to 88648 (cambinol), **p = 0.0014 in the kidney and from 120643 (control) to 21610.6 (cambinol), *p = 0.01 in the liver and
from 9.662.7 (control) to 8.362.3 (cambinol), p = 0.5036 in the brain. Columns, mean values from 4 independent experiments 6SD. C. Relative
luciferase units (RLU) were measured as an indicator of tumor size in mice harboring intrahepatic luciferase-labeled HepG2 tumors. Mice treated with
100 mg/kg cambinol had an overall smaller tumor volume compared to vehicle treated controls. Dots are representative of individual animals, bars
are the mean6SD. D. Total RNA was isolated from HepG2 tumors. DCt values of VEGF mRNA in vehicle treated mice were compared to mice treated
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insight of their intricate association in vivo and in the progression
of aging and tumorigenesis.
Materials and Methods
Cell culture
Human HCC cell lines, Hep3B and HepG2 cells were
purchased from ATCC (LCG Standards) and Huh7 cells were
given by J-F. Dufour (University of Bern, Switzerland) and
originally obtained from the Japanese Collection of Research
Bioresources (JCRB). The VHL-deficient renal cell carcinoma cell
line, RCC4 VHL2/2 and RCC4 VHL+/+ cells [33] were
obtained from G. Camenisch (University of Zu¨rich, Switzerland).
Cell lines were cultured in DMEM medium with 10% fetal bovine
serum, 100 U/ml penicillin and 100 mg/ml streptomycin (Life
Technology). Cells were cultured under normal oxygen conditions
of 21% O2, 5% CO2 at 37uC in a humidified incubator or hypoxic
conditions in a microaerophilic system (Ruskinn, Biotrace
International, UK) at 1% or 0.1% O2 and 5% CO2 humidified
environment.
Chemicals and reagents
Dimethyloxaloylglycine (DMOG) and sirtinol were purchased
from Alexis Biochemicals (Lausen, Switzerland). The proteasome
inhibitor MG132 (Z-LLL-CHO) and cambinol was purchased
from Sigma-Aldrich (Basel, Switzerland). All chemicals were
dissolved in DMSO as stock solutions (DMOG: 100 mmol/L;
sirtinol: 50 mmol/L; cambinol: 50 mmol/L; MG132: 25 mmol/L)
and diluted with cell culture medium to obtain final concentra-
tions. In all experiments, the necessary amount of DMSO was
added to all control conditions to reach the final concentration in
the media as the compound treated cells.
Western blotting
Western blots were performed according to standard protocols.
Briefly, total cell lysates were prepared by direct lysis in modified
RIPA buffer, proteins were separated by SDS-PAGE and
transferred to nitrocellulose membranes. Membranes were
blocked in 5% non-fat dry milk and incubated with primary
antibodies overnight at 4uC. HRP-conjugated secondary antibod-
ies were incubated for 1 hour at room temperature and
membranes were developed with enhanced chemiluminescence
(Western lightening Plus-ECL, Perkin Elmer). Primary antibodies
used were rabbit polyclonal anti-SIRT1 (MW: ,120 kDa), mouse
monoclonal anti-a-tubulin (MW: ,55 kDa) and rabbit polyclonal
anti-Sp1 (MW:,100 kDa) all from Santa Cruz (Santa Cruz,
USA), rabbit polyclonal anti-acetyl-lysine from Cell Signaling
(Allschwil, Switzerland), mouse monoclonal anti-HIF-1a
(MW:,115 kDa) from Alexis Biochemicals (Lausen, Switzerland).
Chicken polyclonal anti-HIF-1a (MW:,115 kDa) antibody was a
courtesy by M. Gassmann (University of Zurich, Switzerland) [43].
HRP-conjugated secondary antibodies used were goat anti-rabbit
(Dako, Baar, Switzerland), goat anti-mouse (Perbio Science S.A,
Lausanne, Switzerland) and rabbit anti-chicken (Promega, Du-
bendorf, Switzerland).
RNA extraction and quantitative RT-PCR
Total RNA was isolated using Trizol Reagent following the
manufacturer’s protocol (Life Technologies). cDNA was synthe-
sized using Omniscript RT Kit (QIagen). Levels of mRNA were
analyzed by quantitated RT-qPCR. Human probes for 18S rRNA
(4310893E), HIF-1a (Hs00153153_m1), EPO (Hs00171267_m1),
CA9 (Hs00154208_m1), SIRT1 (Hs00202021_m1), BNIP3
(Hs00969293_m1), VEGF (Hs00173626_m1) and mouse EPO
(Mm01202755_m1) were obtained from ABI (Applied Biosystems,
Rotkreuz, Switzerland). Relative changes in mRNA were
calculated with the DDCt method. Ct values of target gene
expression (TG) was calculated relative to a reference gene control
(RG) using the following formula DCtTG=CtTG2CtRG. Experi-
mental groups (TG) are normalized to control group (CG):
DDCt=DCtTG2DCtCG, and fold increase = 2
2DDCt.
Immunoprecipitation
For cytoplasmic and nuclear protein fractionation cells were
lysed with lysis buffer [10 mmol/L Hepes (pH 7.9); 10 mmol/L
KCL; 0.1 mmol/L EDTA; 0.1 mmol/L EGTA; 1 mmol/L DDT;
phosphatase inhibitors (Na3VO4, NaF, PMSF); a protease
inhibitor cocktail (Sigma) and 0.5% NP-40]. The lysates were
centrifuged at 14,000 rpm and the supernatant was transferred in
a new tube (cytoplasmic fraction). For the extraction of nuclear
proteins, cell pellet was re-suspended in 20 mmol/L Hepes,
pH 7.9; 400 mmol/L KCL for 15 minutes on ice. Extracts were
centrifuged for 5 min at 2000 rpm and the supernatant was kept
(nuclear fraction). For the immunoprecipitation of SIRT1,
cytoplasmic proteins (1250 mg) and nuclear extracts (250 mg) were
incubated with 2 mg and 1 mg of rabbit polyclonal anti-SIRT1
antibody, respectively (Santa Cruz Biotechnology) or similar
amounts of rabbit IgG1 control antibody overnight at 4uC. The
same procedure was performed for immunoprecipitation of HIF-
1a with a mouse monoclonal anti HIF-1a antibody (Alexis
Biochemicals) or mouse IgG1 control antibody. The lysates were
then incubated for a further hour at 4uC together with 50 ml
(cytoplasmic fraction) or 30 ml (nuclear fraction) of Protein G
magnetic microbeads (Miltenyi Biotec, Bergisch Gladbach,
Germany) and loaded on mcolumns (Miltenyi Biotec) according
to the manufacturer’s protocol. Beads were first extensively
washed with lysis buffer (composed of 2/3 of lysis buffer and 1/
3 of nuclear extraction buffer) and then boiled with Laemmli
sample buffer for five minutes and analyzed by SDS-PAGE as
described before. To check the acetylation level of HIF-1a, cells
were lysed with a lysis buffer containing 1% Triton-X 100, 0.5%
NP-40, 10 mmol/L Tris, 150 mmol/L NaCl, 1 mmol/L EDTA,
1 mmol/L EGTA, phosphatase inhibitors (Na3VO4, NaF, ZnCl2)
and a protease inhibitor cocktail (Sigma). From each sample, 2 mg
of protein were incubated with 2 mg of mouse monoclonal HIF-1a
antibody overnight at 4uC. Five percent of whole cell lysates were
saved as input controls. For immunoprecipitation of HIF-1a the
above described procedure was performed and samples were
analyzed by SDS-PAGE.
Plasmids, transfections and reporter gene assay
Three tandem repeats of the HIF-1 binding site from the
transferrin promoter in the pGL3 luciferase vector (Promega). A
HBS is part of the hypoxia-responsive element (HRE) of HIF
target genes. pGL3-HRE plasmid was co-transfected with Renilla
luciferase control plasmid (pRL-TK) with Effectene transfection
reagent according to the manufacturer’s protocol (Qiagen).
Twenty-four hours after co-transfection, cells were treated with
sirtinol and incubated under hypoxia for 24 hours. Absolute
luminescence was measured according to the Dual-LuciferaseH
with cambinol by RT-qPCR. Dots are representative of individual animals and bars are the mean 6SD. E. Haematoxylin and eosin stain of excised
tumors from mice treated with vehicle or cambinol.
doi:10.1371/journal.pone.0033433.g005
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Reporter Assay protocol (Promega). The firefly luciferase values
were normalized to the corresponding renilla luciferase control
values.
Lentiviral vectors expressing shRNAs and SIRT1 and SIRT1
H363Y
Lentivirus production, titer determination and transduction
were carried out as previously described [71]. Two shRNA against
SIRT1 (clone 1, ID: NM_012238.3-1958s1c1 termed
shSIRT1_1958 and clone 2, ID: NM_012238.3-3206s1c1 termed
shSIRT1_3206) and a non-target shRNA control vector (SHC002)
were obtained from Sigma (Basel, Switzerland). Cells were
transduced overnight and then selected in 1.5 mg/ml puromycin
for 3 to 5 days before experiments were performed. SIRT1 wt
(wildtype) and SIRT1 H363Y (point-mutated) plasmids [46] were
a kind gift from Dr. Michael Potente (University of Frankfurt,
Frankfurt, Germany).
In vivo models
Experiments were performed in strict accordance with Swiss
Federal Veterinary Office article 18 Animal Welfare Act, article
141 Animal Welfare Ordinance and article 30 Animal Experi-
mentation Ordinance. All protocols were approved by Bernese
cantonal authorities, LANAT Amt fu¨r Landwirtschaft und Natur
Veterina¨rdienst (VeD), Permit Nrs: 79/07 and 87/09. All surgery
was performed under anesthesia and animals received post-
surgical analgesia to minimize any potential suffering or
discomfort.
An in vivo systemic, normobaric hypoxia model was performed
as previously described [48]. For HCC orthotopic xenograft
studies 0.56106 luciferase-labelled HepG2 cells were injected into
the subcapsular space of the left liver lobe of 6–8 week old female
Rag2 common gamma-null mice. Tumor growth was monitored
with bioluminescent imaging using CCD camera (NightOWL,
Berthold Technologies, Switzerland). Tumors were excised and
embedded in paraffin or snap frozen in liquid nitrogen for further
analysis.
Statistical Analysis
Unless otherwise indicated, all graphs represent mean values 6
standard deviation (SD). Statistics were performed using unpaired
Students T-test and graphs made using GraphPad Prism software.
Supporting Information
Figure S1 Inhibition of SIRT1 increases DNA-damage
induced acetylated p53. HepG2 cells were pre-treated with
100 mM sirtinol or an equal concentration of DMSO for 4 hours
and then incubated with 17 mM doxorubicin for 0.5, 1, 2, 6 and
18 hours. Total cell lysates were analyzed by Western blot. Cells
treated with sirtinol displayed more acetylated p53 after DNA
damage at earlier time points compared to DMSO-treated
controls.
(TIF)
Figure S2 Inhibition of SIRT1 impairs HIF-1a protein
accumulation in HepG2 and Huh7 cell lines. HepG2 and
Huh7 cells were treated with 100 mM sirtinol or an equivalent
concentration of DMSO (D) for 16 hours and then exposed to
21% O2 (N) or 1% O2 (H) for 4 hours. Whole cell lysates were
analyzed by Western blot using antibodies against HIF-1a. a-
tubulin was used as a loading control. A representative blot of 3
independently performed experiments is shown.
(TIF)
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